The clinical trials for ganaxolone included patients with various conditions such as Fragile X Syndrome, CDKL5 deficiency disorder, CSWS, Lennox-Gastaut, and PCDH19. The gene discussed is PCDH19; the disease is developmental and/or epileptic encephalopathy with spike-wave activation in sleep.